Rasyid Nur Rahmah, Miskad Upik Anderiani, Cangara Muhammad Husni, Wahid Syarifuddin, Achmad Djumadi, Tawali Suryani, Mardiati Mardiati
Department of Anatomical Pathology, Faculty of Medicine, Hasanuddin University, Makassar 90245, Indonesia.
Anatomical Pathology Laboratory, Hasanuddin University Hospital, Makassar 90245, Indonesia.
Curr Oncol. 2024 Nov 25;31(12):7476-7493. doi: 10.3390/curroncol31120552.
Colorectal cancer (CRC) is a prevalent malignancy with a high mortality rate. Tumor-infiltrating lymphocytes (TILs) play a crucial role in the immune response against tumors. Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) are key immune checkpoints regulating T cells in the tumor microenvironment. This study aimed to assess the relationships among PD-1 expression on TILs, PD-L1 expression in tumors, and TIL grading in colorectal adenocarcinoma.
A cross-sectional design was employed to analyze 130 colorectal adenocarcinoma samples. The expression of PD-1 and PD-L1 was assessed through immunohistochemistry. A semi-quantitative scoring system was applied. Statistical analysis with the chi-square test was performed to explore correlations, with the data analyzed in SPSS version 27.
PD-1 expression on TILs significantly correlated with a higher TIL grading ( < 0.001), while PD-L1 expression in tumors showed an inverse correlation with TIL grading ( < 0.001).
The expression of PD-1 on TILs and PD-L1 on tumor cells correlated significantly with the grading of TILs in colorectal adenocarcinoma. This finding shows potential as a predictive biomarker for PD-1/PD-L1 blockade therapy. Further studies are needed to strengthen these results.
结直肠癌(CRC)是一种常见的恶性肿瘤,死亡率很高。肿瘤浸润淋巴细胞(TILs)在抗肿瘤免疫反应中起关键作用。程序性死亡蛋白1(PD-1)和程序性死亡配体1(PD-L1)是调节肿瘤微环境中T细胞的关键免疫检查点。本研究旨在评估结直肠腺癌中TILs上PD-1表达、肿瘤中PD-L1表达与TIL分级之间的关系。
采用横断面设计分析130例结直肠腺癌样本。通过免疫组织化学评估PD-1和PD-L1的表达。应用半定量评分系统。采用卡方检验进行统计分析以探索相关性,数据在SPSS 27版中进行分析。
TILs上的PD-1表达与较高的TIL分级显著相关(<0.001),而肿瘤中的PD-L1表达与TIL分级呈负相关(<0.001)。
结直肠腺癌中TILs上的PD-1表达和肿瘤细胞上的PD-L1表达与TIL分级显著相关。这一发现显示出作为PD-1/PD-L1阻断治疗预测生物标志物的潜力。需要进一步研究来强化这些结果。